Pharmacotherapeutic strategies for standard treatment-resistant psoriasis

References

• Rahman M, Zaki Ahmad M, Kazmi I, et al. Insight into the biomarkers as the novel anti-psoriatic drug discovery tool: a contemporary viewpoint. Curr Drug Discov Technol. 2012;9(1):48–62.
   PubMedGoogle Scholar
• Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–1185.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–298.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Yoles A, Lombardi K, et al. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998;39(3):447–450.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158.
   PubMed Web of Science ®Google Scholar
• Sandoval LF, Davis SA, Feldman SR. Dermatologists’ knowledge of and preferences regarding topical steroids. J Drugs Dermatol. 2013;12(7):786–789.
   PubMed Web of Science ®Google Scholar
• Resnick SD, Hornung R, Konrad TR. A comparison of dermatologists and generalists. Management of childhood atopic dermatitis. Arch Dermatol. 1996;132(9):1047–1052.
   PubMedGoogle Scholar
• Samarasekera EJ, Sawyer L, Wonderling D, et al. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol. 2013;168(5):954–967.
   PubMed Web of Science ®Google Scholar
• Storm A, Andersen SE, Benfeldt E, et al. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59(1):27–33.
   PubMed Web of Science ®Google Scholar
• Miller JJ, Roling D, Margolis D, et al. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol. 1999;41(4):546–549.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Linkner RV, Suarez-Farinas M, et al. An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis. J Am Acad Dermatol. 2014;71(5):954–959.e1.
   PubMed Web of Science ®Google Scholar
• Zschocke I, Mrowietz U, Karakasili E, et al. Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 2):4–9.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology. 1998;197(1):31–36.
   PubMed Web of Science ®Google Scholar
• Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51(2):212–216.
   PubMed Web of Science ®Google Scholar
• Alinia H, Moradi Tuchayi S, Smith JA, et al. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759–764.
   PubMed Web of Science ®Google Scholar
• Goren A, Carter C, Lee S. Patient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasis. J Dermatolog Treat. 2016;27(1):43–50.
   PubMed Web of Science ®Google Scholar
• Chan SA, Hussain F, Lawson LG, et al. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat. 2013;24(1):64–69.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt ML, Umar N, Schmieder A, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol. 2013;27(2):187–198.
   PubMed Web of Science ®Google Scholar
• Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607–613.
   PubMed Web of Science ®Google Scholar
• Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61–67.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Levi E, Pathak P, et al. Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs. J Med Econ. 2013;16(12):1405–1413.
   PubMedGoogle Scholar
• Kalia S, Toosi B, Bansback N, et al. Assessing adherence with phototherapy protocols. J Am Acad Dermatol. 2014;71(6):1259–1261.
   PubMed Web of Science ®Google Scholar
• Oussedik E, Foy CG, Masicampo EJ, et al. Accountability: a missing construct in models of adherence behavior and in clinical practice. Patient Prefer Adherence. 2017;11:1285–1294.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Feldman RS. Practical ways to improve patient adherence. Columbia, SC: CreateSpace Independent Publishing Platform; 2017. p. 194.
   Google Scholar
• Uhlenhake EE, Kurkowski D, Feldman SR. Conversations on psoriasis–what patients want and what physicians can provide: a qualitative look at patient and physician expectations. J Dermatolog Treat. 2010;21(1):6–12.
   PubMed Web of Science ®Google Scholar
• Housman TS, Mellen BG, Rapp SR, et al. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70(6):327–332.
   PubMed Web of Science ®Google Scholar
• Hong CH, Papp KA, Lophaven KW, et al. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. J Eur Acad Dermatol Venereol. 2017;31(11):1876–1883.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol. 2009;10(6):397–406.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Taheri A, Feldman SR. Once-daily topical treatment for psoriasis: calcipotriene + betamethasone two-compound topical formulation. Clin Cosmet Investig Dermatol. 2014;7:19–22.
   Google Scholar
• Koek MB, Buskens E, van Weelden H, et al. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study). Bmj. 2009;338:b1542.
   PubMed Web of Science ®Google Scholar
• Carlin CS, Callis KP, Krueger GG. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol. 2003;139(4):436–442.
   PubMedGoogle Scholar
• Fleischer AB Jr., Clark AR, Rapp SR, et al. Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial. J Invest Dermatol. 1997;109(2):170–174.
   PubMed Web of Science ®Google Scholar
• Balato N, Megna M, Di Costanzo L, et al. Educational and motivational support service: a pilot study for mobile-phone-based interventions in patients with psoriasis. Br J Dermatol. 2013;168(1):201–205.
   PubMed Web of Science ®Google Scholar
• Katare OP, Raza K, Singh B, et al. Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian J Dermatol Venereol Leprol. 2010;76(6):612–621.
   PubMed Web of Science ®Google Scholar
• Rahman M, Beg S, Anwar F, et al. Nanotechnology-based nano-bullets in antipsoriatic drug delivery; 2016. p. 157–166.
   Google Scholar
• Rahman M, Kumar V, Beg S, et al. Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art. Artif Cells Nanomed Biotechnol. 2016;44(7):1597–1608.
   PubMed Web of Science ®Google Scholar
• Nijsten T, Margolis DJ, Feldman SR, et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol. 2005;52(3 Pt 1):434–444.
   PubMed Web of Science ®Google Scholar
• Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136–139.
   PubMed Web of Science ®Google Scholar
• Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222(4):363–374.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Evans C, Russell MW. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatolog Treat. 2005;16(1):37–42.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Dam TN, et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091–1096.
   PubMed Web of Science ®Google Scholar
• Yeung H, Wan J, Van Voorhees AS, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68(1):64–72.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Wan J, Callis Duffin K, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012;148(4):487–494.
   PubMedGoogle Scholar
• Arnold T, Schaarschmidt ML, Herr R, et al. Drug survival rates and reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges. 2016;14(11):1089–1099.
   PubMed Web of Science ®Google Scholar
• Harnett J, Wiederkehr D, Gerber R, et al. Primary nonadherence, associated clinical outcomes, and health care resource use among patients with rheumatoid arthritis prescribed treatment with injectable biologic disease-modifying antirheumatic drugs. J Manag Care Spec Pharm. 2016;22(3):209–218.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115.
   PubMed Web of Science ®Google Scholar
• Bhosle MJ, Feldman SR, Camacho FT, et al. Medication adherence and health care costs associated with biologics in medicaid-enrolled patients with psoriasis. J Dermatolog Treat. 2006;17(5):294–301.
   PubMed Web of Science ®Google Scholar
• West C, Narahari S, O’Neill J, et al. Adherence to adalimumab in patients with moderate to severe psoriasis. Dermatol Online J. 2013;19(5):18182.
   PubMedGoogle Scholar
• Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One. 2012;7(4):e33486.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165–178.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Guerra I, Munoz-Linares P, et al. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35(9):971–986.
   PubMed Web of Science ®Google Scholar
• Hsu L, Armstrong AW. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol. 2013;9(10):949–958.
   PubMed Web of Science ®Google Scholar
• Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170(2):261–273.
   PubMed Web of Science ®Google Scholar
• Lombardi G, Perego S, Sansoni V, et al. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. BMJ Open. 2016;6(12):e011941.
   PubMed Web of Science ®Google Scholar
• Marinari B, Botti E, Bavetta M, et al. Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations. Drug Dev Res. 2014;75(Suppl 1):S11–4.
   PubMedGoogle Scholar
• Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFalpha biologics in rheumatic diseases. Clin Rheumatol. 2013;32(10):1429–1435.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–542.
   PubMed Web of Science ®Google Scholar
• Krathen RA, Berthelot CN, Hsu S. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients. J Drugs Dermatol. 2006;5(3):251–254.
   PubMedGoogle Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1–15.
   PubMed Web of Science ®Google Scholar
• Asahina A, Nakagawa H, Etoh T, et al. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37(4):299–310.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–2022.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304–1312.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010;9(8):928–937.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–128.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56(9):1226–1231.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhao Y, Navaratnam P, et al. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(3):201–209.
   PubMedGoogle Scholar
• Seale L, Cardwell LA, Feldman SR. Adherence to biologics in patients with psoriasis. Expert Rev Clin Immunol. 2018;14(2):155–161.
   PubMed Web of Science ®Google Scholar
• Sandoval LF, Huang KE, Feldman SR. Adherence to ustekinumab in psoriasis patients. J Drugs Dermatol. 2013;12(10):1090–1092.
   PubMed Web of Science ®Google Scholar
• Zhang M, Brenneman SK, Carter CT, et al. Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis. Patient Prefer Adherence. 2015;9:777–784.
   PubMed Web of Science ®Google Scholar
• Cassano N, Loconsole F, Miracapillo A, et al. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Talpharanta Plastic Study Group. Int J Immunopathol Pharmacol. 2010;23(3):797–802.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606.
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357(9271):1842–1847.
   PubMed Web of Science ®Google Scholar
• Zweegers J, Otero ME, van Den Reek JM, et al. Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: a systematic review. Acta Derm Venereol. 2016;96(4):453–458.
   PubMed Web of Science ®Google Scholar
• Busard C, Zweegers J, Limpens J, et al. Combined use of systemic agents for psoriasis: a systematic review. JAMA Dermatol. 2014;150(11):1213–1220.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Cotena C, et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol. 2008;158(6):1345–1349.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Bagel J, Van Voorhees AS, et al. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151(4):432–438.
   PubMed Web of Science ®Google Scholar
• Lynde CW, Gupta AK, Guenther L, et al. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatolog Treat. 2012;23(4):261–267.
   PubMed Web of Science ®Google Scholar
• Rahman M, Beg S, Ahmad MZ, et al. Omega-3 fatty acids as pharmacotherapeutics in psoriasis: current status and scope of nanomedicine in its effective delivery. Curr Drug Targets. 2013;14(6):708–722.
   PubMed Web of Science ®Google Scholar
• Hegde M, Zanwar A, Adekar SP. Omega-3 fatty acids: keys to nutritional health. Switzerland: Springer International Publishing; 2016.
   Google Scholar
• Baboota S, Rahman M, Kumar DA, et al. Submicron size formulation of linseed oil containing omega3 fatty acid for topical delivery. 2012.
   Google Scholar
• Honda H, Umezawa Y, Kikuchi S, et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44(9):1015–1019.
   PubMed Web of Science ®Google Scholar
• Leman J, Burden AD. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. Br J Dermatol. 2012;167(Suppl 3):12–20.
   PubMed Web of Science ®Google Scholar
• Robertson J, Koerner P, Staskon F, et al. Retrospective analysis studying clinical outcomes in psoriasis patients who switched from a biologic medication to either secukinumab or ixekizumab. J Drug Assess. 2018;7(sup1):23.
   Google Scholar
• Galluzzo M, Talamonti M, De Simone C, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018;18(7):727–735.
   PubMed Web of Science ®Google Scholar
• Notario J, Deza G, Vilarrasa E, et al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatolog Treat. 2018;1–21.
   Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Bernardini N, et al. Psoriasis area and severity index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. J Eur Acad Dermatol Venereol. 2018;32(10):1737–1744.
   PubMed Web of Science ®Google Scholar
• Qiang JK, Shahbaz A, Kim W, et al. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study. J Am Acad Dermatol. 2016;74(1):176–177.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Cazzaniga S, Chimenti S, et al. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry. J Am Acad Dermatol. 2014;70(2):257–62.e3.
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Bissonnette R, Teixeira HD, et al. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. J Am Acad Dermatol. 2016;75(3):612–618.e6.
   PubMed Web of Science ®Google Scholar
• Talamonti M, D’Adamio S, Bianchi L, et al. The role of pharmacogenetics in chronic plaque psoriasis: update of the literature. Mol Diagn Ther. 2017;21(5):467–480.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169(2):458–463.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Chimenti S, et al. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: outcome and long-term follow-up. J Am Acad Dermatol. 2016;74(2):374–375.
   PubMed Web of Science ®Google Scholar
• Li K, Huang CC, Randazzo B, et al. HLA-C*06:02 Allele and response to IL-12/23 inhibition: results from the ustekinumab phase 3 psoriasis program. J Invest Dermatol. 2016;136(12):2364–2371.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Zangrilli A, et al. HLA-C*06:02 does not predispose to clinical response following long-term adalimumab treatment in psoriatic patients: a retrospective cohort study. Mol Diagn Ther. 2017;21(3):295–301.
   PubMed Web of Science ®Google Scholar
• Caldarola G, Sgambato A, Fanali C, et al. HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients. Pharmacogenet Genomics. 2016;26(9):423–427.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhao Y, Zhou H, et al. Economic impact of above-label dosing with etanercept, adalimumab, or ustekinumab in patients with psoriasis. J Manag Care Spec Pharm. 2017;23(5):583–589.
   PubMedGoogle Scholar
• Cather JC, Crowley JJ. Use of biologic agents in combination with other therapies for the treatment of psoriasis. Am J Clin Dermatol. 2014;15(6):467–478.
   PubMed Web of Science ®Google Scholar